Research ArticleArticle
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen
Evan F. Ekman, Joseph S. Gimbel, Alfonso E. Bello, Michael D. Smith, David S. Keller, Karen M. Annis, Mark T. Brown, Christine R. West and Kenneth M. Verburg
The Journal of Rheumatology November 2014, 41 (11) 2249-2259; DOI: https://doi.org/10.3899/jrheum.131294
Evan F. Ekman
From Appalachian Regional Orthopaedic and Sports Medicine, Boone, North Carolina; Phoenix Orthopedic Surgeons, Phoenix, Arizona; Illinois Bone and Joint Institute, Glenview, Illinois; Pfizer Inc., Groton, Connecticut,
USA.
Joseph S. Gimbel
Alfonso E. Bello
Michael D. Smith
David S. Keller
Karen M. Annis
Mark T. Brown
Christine R. West
REFERENCES
- 1.↵
- 2.↵
- 3.↵American Academy of Orthopaedic Surgeons. The treatment of osteoarthritis of the knee (non-arthroplasty). [Internet. Accessed September 16.] Available from: www.aaos.org/research/guidelines/TreatmentofOsteoarthritisoftheKneeGuideline.pdf.
- 4.↵
- Jordan KM,
- Arden NK,
- Doherty M,
- Bannwarth B,
- Bijlsma JW,
- Dieppe P,
- et al.
- 5.↵
- 6.↵
- 7.↵
- 8.↵
- 9.↵
- 10.↵
- 11.↵
- 12.↵
- 13.↵
- 14.↵
- Nagashima H,
- Suzuki M,
- Araki S,
- Yamabe T,
- Muto C
- 15.↵
- 16.↵
- 17.↵
- Altman R,
- Asch E,
- Bloch D,
- Bole G,
- Borenstein D,
- Brandt K,
- et al.
- 18.↵
- Kellgren JH,
- Lawrence JS
- 19.↵
- 20.↵
- Stengaard-Pedersen K,
- Ekesbo R,
- Karvonen AL,
- Lyster M
- 21.↵
- 22.↵
- 23.↵
- Pfizer Inc
- 24.↵
- Hochberg MC,
- Abramson SB,
- Hungerford DS,
- McCarthy E,
- Vignon EP,
- Smith MD,
- et al.
- 25.↵U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry: clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis (OA). [Internet. Accessed August 7, 2014.] Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071577.pdf.
- 26.↵
- 27.↵
- 28.↵FDA Center for Drug Evaluation and Research. Background materials. Meeting of the Arthritis Advisory Committee (AAC). [Internet. Accessed August 7, 2014]. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295202.pdf.
- 29.↵FDA Center for Drug Evaluation and Research (CDER). Background materials addendum. [Internet. Accessed August 7, 2014.] Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295203.pdf.
In this issue
The Journal of Rheumatology
Vol. 41, Issue 11
1 Nov 2014
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen
Evan F. Ekman, Joseph S. Gimbel, Alfonso E. Bello, Michael D. Smith, David S. Keller, Karen M. Annis, Mark T. Brown, Christine R. West, Kenneth M. Verburg
The Journal of Rheumatology Nov 2014, 41 (11) 2249-2259; DOI: 10.3899/jrheum.131294
Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen
Evan F. Ekman, Joseph S. Gimbel, Alfonso E. Bello, Michael D. Smith, David S. Keller, Karen M. Annis, Mark T. Brown, Christine R. West, Kenneth M. Verburg
The Journal of Rheumatology Nov 2014, 41 (11) 2249-2259; DOI: 10.3899/jrheum.131294